Dec 11, 2014Phase1 Dose Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of ANAVEX2-73CNS Summit 2014, Boca Raton, FLOle Voges, Ingo Weigmann, Norman Bitterlich, Christoph Schindler and Christopher MisslingView Poster
CNS Summit 2014, Boca Raton, FLOle Voges, Ingo Weigmann, Norman Bitterlich, Christoph Schindler and Christopher MisslingView Poster
Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer’s Disease to EMA
Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer’s Disease Journal